|
**Overview**: Acute Myeloid Leukemia PCR Panel**Introduction**: The Acute Myeloid Leukemia PCR Panel is a diagnostic tool designed to categorize acute myeloid leukemia using whole blood or bone marrow samples. In India, AML is a common adult leukemia (incidence ~2-3 per 100,000), with pediatric cases also significant, and high mortality due to delayed diagnosis, limited molecular labs, and treatment access in rural areas. Molecular markers (FLT3-ITD, NPM1, CEBPA, RUNX1-RUNX1T1, PML-RARA) guide prognosis and targeted therapy. High morbidity from underdiagnosis in low-SES populations, overlap with infections, and poor outcomes in resource-limited settings. Per molecular pathology and hematology practices aligned with ICMR guidelines, the test employs PCR for detailed mutation analysis over 1-2 days with high sensitivity/specificity, valuable for risk stratification in AML. This diagnostic falls under leukemia screening and targets patients with suspected AML, addressing accurate categorization to guide chemotherapy or targeted agents. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating personalized management, and improving survival rates. Its blood/bone marrow-based approach ensures reliable detection.**Other Names**: AML PCR Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.**Historical Milestone**: Expanded with PCR for key mutations; in India, prominence with rising leukemia molecular diagnostics.**Purpose**: The test screens for 5 parameters including FLT3-ITD to categorize AML, assess prognostic markers, inform targeted treatment.**Test Parameters**: 1. FLT3-ITD, 2. NPM1, 3. CEBPA, 4. RUNX1-RUNX1T1, 5. PML-RARA.**Pretest Condition**: No fasting required; patients should report fatigue, fever, bleeding, or bone pain.**Specimen**: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on symptoms, fever, bleeding, prior chemotherapy, or family cancer history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated AML including rapid progression, benefits of early detection, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low blast count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate AML subtype, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if suspicion persists.**Specialist Consultation**: Hematologists or oncologists should be consulted for case management, treatment planning, and coordination with cancer programs.**Additional Supporting Tests**: Bone marrow biopsy, cytogenetics, flow cytometry for confirmation.**Test Limitations**: The test may miss rare mutations or require fresh samples; comprehensive approach with clinical correlation required.**References**: Indian Journal of Hematology 2024, AML Studies India 2023. |
